Peking Union Medical College Hospital: Biliary Tract Neoplasms trials

The registry lists 16 Biliary Tract Neoplasms studies with Peking Union Medical College Hospital as lead sponsor. 10 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 14No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract CancerRecruitingNCT07704177Phase 2
• A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.RecruitingNCT07679399Phase 2
• Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract CancerRecruitingNCT07670273Phase 2
• An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.RecruitingNCT07282262Phase 2
• Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract CancerRecruitingNCT07267078Phase 2
• Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract CancerNot yet recruitingNCT07159217Phase 2
• Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract CancerRecruitingNCT07159204Phase 2
• Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerRecruitingNCT06362317Phase 2
• Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerRecruitingNCT05935579Phase 2
• Hepatobiliary Tumors Tissue Samples AcquisitionRecruitingNCT04445532
• Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC ImmunotherapyActive, not recruitingNCT06074029Phase 1/2
• Lenvatinib in Patients With Previously Treated Advanced Biliary Tract CancerCompletedNCT04656249Phase 2
• Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract CancerCompletedNCT04642664Phase 2
• Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract CancersStatus unknownNCT04211168Phase 2
• Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant TumorsStatus unknownNCT04010071Phase 2
• Precise Treatment in Hepatobiliary Cancers (PTHBC)Status unknownNCT02715089